Pridopidina (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 8 | Huntington disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-000904-24-IT (EUCTR) | 15/09/2015 | 23/02/2018 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington's Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidina Product Code: TV-7820 INN or Proposed INN: Pridopidina Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidina Product Code: TV-7820 INN or Proposed INN: Pridopidina Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Italy |